imatinib mesylate — CareFirst (Caremark)

Initial criteria

• Requested medication used as subsequent therapy in combination with systemic corticosteroids

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months